Comparison of the clinical features between the NIH− and the NIH+ groups
| Characteristics . | NIH− (n = 88) . | NIH+ (n = 78) . | P . | |
|---|---|---|---|---|
| Age at HCT* | 39.6 ± 15.5 | 42.0 ± 15.45 | .325 | |
| Weight, kg* | 70.9 ± 18.0 | 65.8 ± 14.88 | .050 | |
| KPS* | 75.1 ± 12.3 | 74.0 ± 11.6 | .551 | |
| TLC, %predicted* | 69.8 ± 17.0 | 79.1 ± 17.7 | <.001 | |
| RV, %predicted* | 83.8 ± 34.2 | 98.3 ± 48.4 | .027 | |
| FVC, %predicted, pre-bronchodilator† | 59.5 ± 17.8 | 66.4 ± 15.8 | .009 | |
| FEV1, %predicted, pre-bronchodilator* | 56.6 ± 14.9 | 43.3 ± 15.0 | <.001 | |
| FEF 25-75%, %predicted† | 58.4 ± 33.2 | 19.1 ± 10.0 | <.001 | |
| FEV1/FVC, %, pre-bronchodilator† | 76.7 ± 12.3 | 51.6 ± 13.8 | <.001 | |
| DLCO adj, %predicted* | 53.5 ± 17.9 | 54.0 ± 15.3 | .848 | |
| Time from HCT to cGVHD diagnosis (days)* | 361.0 ± 332.2 | 273.2 ± 357.0 | .103 | |
| Time from HCT to adjudicative PFT (days)* | 2178.0 ± 1724.1 | 2040.9 ± 1405.4 | .578 | |
| Different types of cGVHD treatment*,‡ | 3.8 ± 1.9 | 5.1 ± 2.2 | <.001 | |
| Recipient sex§ | Male | 57 (64.7) | 35 (44.8) | .010 |
| Recipient race§ | White | 78 (88.6) | 70 (89.7) | .819 |
| HCT location§ | Local | 81 (92.0) | 73 (93.6) | .701 |
| NIH | 7 (8.0) | 5 (6.4) | ||
| Pre-HCT tobacco use§ | 68 (77.3) | 47 (60.3) | .018 | |
| HCT indication§ | AML, MDS, ALL | 47 (53.4) | 49 (62.8) | .421 |
| CML, MPN | 9 (10.2) | 10 (12.8) | ||
| CLL, HL, NHL, MM | 27 (30.7) | 16 (10.5) | ||
| Others | 5 (5.7) | 3 (3.8) | ||
| Disease status at HCT§ | CR | 46 (52.3) | 46 (59.0) | .619 |
| HLA§ | MRD | 48 (54.5) | 42 (53.8) | .937 |
| MUD | 29 (33.0) | 24 (30.8) | ||
| MMUD | 8 (9.1) | 8 (10.3) | ||
| Haploidentical | 3 (3.4) | 4 (5.1) | ||
| Stem cell source§ | PB | 69 (78.4) | 69 (88.5) | .150 |
| BM | 17 (19.3) | 9 (11.5) | ||
| Conditioning§ | RIC | 39 (44.3) | 30 (38.5) | .448 |
| MA | 48 (54.5) | 47 (60.3) | ||
| Busulfan§ | 40 (45.5) | 36 (46.2) | .662 | |
| TBI§ | 36 (40.9) | 28 (38.9) | .924 | |
| GVHD prophylaxis | CNI + MTX | 44 (50.0) | 38 (48.7) | .921 |
| Second malignancy§ | 18 (20.5) | 16 (20.5) | .993 | |
| Acute GVHD§ | 23 (26.1) | 23 (29.5) | .630 | |
| cGVHD global severity§ | Mild | 1 (1.1) | 0 | .336 |
| Moderate | 10 (11.4) | 5 (6.4) | ||
| Severe | 77 (87.5) | 73 (93.6) | ||
| Skin cGVHD§ | 74 (84.1) | 54 (69.2) | .005 | |
| Joints/fascia cGVHD§ | 68 (77.3) | 45 (57.7) | .007 | |
| Liver cGVHD§ | 49 (55.7) | 40 (51.3) | .570 | |
| GI tract cGVHD§ | 39 (44.3) | 34 (43.6) | .925 | |
| Relapse/refractory primary malignancy§ | 11 (12.5) | 11 (14.1) | .761 | |
| Characteristics . | NIH− (n = 88) . | NIH+ (n = 78) . | P . | |
|---|---|---|---|---|
| Age at HCT* | 39.6 ± 15.5 | 42.0 ± 15.45 | .325 | |
| Weight, kg* | 70.9 ± 18.0 | 65.8 ± 14.88 | .050 | |
| KPS* | 75.1 ± 12.3 | 74.0 ± 11.6 | .551 | |
| TLC, %predicted* | 69.8 ± 17.0 | 79.1 ± 17.7 | <.001 | |
| RV, %predicted* | 83.8 ± 34.2 | 98.3 ± 48.4 | .027 | |
| FVC, %predicted, pre-bronchodilator† | 59.5 ± 17.8 | 66.4 ± 15.8 | .009 | |
| FEV1, %predicted, pre-bronchodilator* | 56.6 ± 14.9 | 43.3 ± 15.0 | <.001 | |
| FEF 25-75%, %predicted† | 58.4 ± 33.2 | 19.1 ± 10.0 | <.001 | |
| FEV1/FVC, %, pre-bronchodilator† | 76.7 ± 12.3 | 51.6 ± 13.8 | <.001 | |
| DLCO adj, %predicted* | 53.5 ± 17.9 | 54.0 ± 15.3 | .848 | |
| Time from HCT to cGVHD diagnosis (days)* | 361.0 ± 332.2 | 273.2 ± 357.0 | .103 | |
| Time from HCT to adjudicative PFT (days)* | 2178.0 ± 1724.1 | 2040.9 ± 1405.4 | .578 | |
| Different types of cGVHD treatment*,‡ | 3.8 ± 1.9 | 5.1 ± 2.2 | <.001 | |
| Recipient sex§ | Male | 57 (64.7) | 35 (44.8) | .010 |
| Recipient race§ | White | 78 (88.6) | 70 (89.7) | .819 |
| HCT location§ | Local | 81 (92.0) | 73 (93.6) | .701 |
| NIH | 7 (8.0) | 5 (6.4) | ||
| Pre-HCT tobacco use§ | 68 (77.3) | 47 (60.3) | .018 | |
| HCT indication§ | AML, MDS, ALL | 47 (53.4) | 49 (62.8) | .421 |
| CML, MPN | 9 (10.2) | 10 (12.8) | ||
| CLL, HL, NHL, MM | 27 (30.7) | 16 (10.5) | ||
| Others | 5 (5.7) | 3 (3.8) | ||
| Disease status at HCT§ | CR | 46 (52.3) | 46 (59.0) | .619 |
| HLA§ | MRD | 48 (54.5) | 42 (53.8) | .937 |
| MUD | 29 (33.0) | 24 (30.8) | ||
| MMUD | 8 (9.1) | 8 (10.3) | ||
| Haploidentical | 3 (3.4) | 4 (5.1) | ||
| Stem cell source§ | PB | 69 (78.4) | 69 (88.5) | .150 |
| BM | 17 (19.3) | 9 (11.5) | ||
| Conditioning§ | RIC | 39 (44.3) | 30 (38.5) | .448 |
| MA | 48 (54.5) | 47 (60.3) | ||
| Busulfan§ | 40 (45.5) | 36 (46.2) | .662 | |
| TBI§ | 36 (40.9) | 28 (38.9) | .924 | |
| GVHD prophylaxis | CNI + MTX | 44 (50.0) | 38 (48.7) | .921 |
| Second malignancy§ | 18 (20.5) | 16 (20.5) | .993 | |
| Acute GVHD§ | 23 (26.1) | 23 (29.5) | .630 | |
| cGVHD global severity§ | Mild | 1 (1.1) | 0 | .336 |
| Moderate | 10 (11.4) | 5 (6.4) | ||
| Severe | 77 (87.5) | 73 (93.6) | ||
| Skin cGVHD§ | 74 (84.1) | 54 (69.2) | .005 | |
| Joints/fascia cGVHD§ | 68 (77.3) | 45 (57.7) | .007 | |
| Liver cGVHD§ | 49 (55.7) | 40 (51.3) | .570 | |
| GI tract cGVHD§ | 39 (44.3) | 34 (43.6) | .925 | |
| Relapse/refractory primary malignancy§ | 11 (12.5) | 11 (14.1) | .761 | |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; CR, complete remission; GC, GVHD control; HL, Hodgkin’s lymphoma; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MM, multiple myeloma; MMUD, mismatched unrelated donor; MPN, myeloproliferative neoplasm; MRD, matched related donor; MUD, matched unrelated donor; NHL, non-Hodgkin’s lymphoma; PB, peripheral blood; RIC, reduced intensity conditioning; RV, residual volume; TBI, total body irradiation.
Mean ± SD, independent sample t test.
Mean ± SD, Mann-Whitney U test.
Excluding topical treatment such as topical corticosteroids.
Count (percentage), χ2 test.